Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0010)
Name |
Capsaicin
|
||||
---|---|---|---|---|---|
Synonyms |
Capsaicin; 404-86-4; Zostrix; (E)-Capsaicin; Qutenza; CAPSAICINE; Axsain; Styptysat; Isodecenoic acid vanillylamide; Ausanil; trans-Capsaicin; E-CAPSAICIN; NGX-4010; trans-8-Methyl-N-vanillyl-6-nonenamide; Mioton; (E)-8-Methyl-N-vanillyl-6-nonenamide; FEMA No. 3404; Dolenon; Ovocap; Capzasin-hp; Caswell No. 158; Togarashi orenji; ALGRX 4975; C18H27NO3; Ratden pe 40; NCI-C56564; NSC 56353; Capsaicinoid; CCRIS 1588; CHEBI:3374; HSDB 954; Transacin; 8-Methyl-N-vanillyl-trans-6-nonenamide; 8-Methyl-N-Vanillyl-6-Nonenamide; Cntx-4975; NGX-1998; EINECS 206-969-8; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; UNII-S07O44R1ZM; MFCD00017259; NSC-56353; trans-Capsaicin-d3; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; EPA Pesticide Chemical Code 070701; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; BRN 2816484; ALGRX-4975; S07O44R1ZM; DTXSID9020241; 8-Methyl-N-vanillyl-6-nonenamide, (E)-; Capsaicin (JAN/USP); NSC56353; ZOSTRIX (TN); 1217899-52-9; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; DTXCID30241; CHEMBL294199; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; Capsaicin [in oleoresin of capsicum]; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; NCGC00017337-02; 8-Methyl-N-vanillyl-(trans)-6-nonenamide; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; 7553-53-9; CAPSAICIN (MART.); CAPSAICIN [MART.]; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; Capsaicin [USAN]; CAPSAICIN (USP MONOGRAPH); CAPSAICIN [USP MONOGRAPH]; Capsicine; Vanilloid; Zacin; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-; Capsaicin (in oleoresin of capsicum); (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; NGX 4010; SR-05000001861; capsaicinum; neurotoxic; Capsaicina; Isodecenoate; Zucapsaicin;Civamide;cis-Capsaicin; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; Adlea; TNP00277; (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl-non-6-enamide; (E)-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; epsilon-capsaicin; capsacin(E); Qutenza;Vanilloid; Zostrix HP; 8 Methyl N Vanillyl 6 Nonenamide; Capsaicin,(S); 4DY; CAS-404-86-4; Prestwick_204; Capsaicin (Natural); depletes Substance P; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; starbld0019180; Capsaicin [USP:INN]; CAPSAICIN [INN]; CAPSAICIN [JAN]; CAPSAICIN [MI]; isoamyl4-methoxycinnamate; 6-Nonenamide, (E)-; CAPSAICIN [HSDB]; CAPSAICIN [INCI]; Prestwick2_000879; Prestwick3_000879; Spectrum5_000538; CAPSAICIN [VANDF]; CAPSAICIN, NATURAL; UPCMLD-DP092; CAPSAICIN [USP-RS]; CAPSAICIN [WHO-DD]; SCHEMBL8085; SCHEMBL8086; MR3H3; BSPBio_000957; BSPBio_001548; BSPBio_002917; CAPSAICIN [EMA EPAR]; MLS002154049; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; Capsaicin, analytical standard; SPECTRUM1501128; BPBio1_001053; GTPL2486; MEGxp0_001448; CAPSAICIN [ORANGE BOOK]; Methyl-N-vanillyl-6-noneneamide; UPCMLD-DP092:001; UPCMLD-DP092:002; BDBM20461; BDBM86537; CHEBI:94524; HMS501B16; HMS1361N10; HMS1570P19; HMS1791N10; HMS1921H11; HMS1989N10; HMS2089N11; HMS2092D21; HMS2097P19; HMS2230O23; HMS3402N10; HMS3414F11; HMS3649N15; HMS3678F11; Pharmakon1600-01501128; 8-Methyl-N-vanillyl-6E-nonenamide; AMY25669; NGX-3781; NGX-7325; NSC_2548; Tox21_110817; Tox21_200315; BBL027836; CCG-39657; CCG-39908; EI-125; HB1179; HY-10448A; LMFA08020085; NSC757844; s1990; STL372889; (E)8-methyl-N-vanillyl-6-Nonenamide; AKOS007930159; (6E)-N-; CS-1518; DB06774; KS-5181; NSC-757844; SDCCGMLS-0066678.P001; TQ-1018; Capsaicin 10 microg/mL in Acetonitrile; Capsaicin, >=95%, from Capsicum sp.; IDI1_000354; IDI1_034018; SMP2_000337; USEPA/OPP Pesticide Code: 070701; NCGC00017337-03; NCGC00017337-04; NCGC00017337-05; NCGC00017337-06; NCGC00017337-07; NCGC00017337-08; NCGC00017337-09; NCGC00017337-10; NCGC00017337-11; NCGC00017337-12; NCGC00017337-13; NCGC00017337-17; NCGC00017337-18; NCGC00090853-01; NCGC00090853-02; NCGC00090853-03; NCGC00090853-04; NCGC00090853-06; NCGC00090853-07; NCGC00090853-08; NCGC00090853-09; NCGC00090853-10; NCGC00090853-11; NCGC00090853-12; NCGC00257869-01; AC-10114; CAS_404-86-4; HY-10448; SMR000718774; CAPSAICIN (CONSTITUENT OF CAPSICUM); SBI-0052593.P002; CS-0181240; M1149; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); C-1700; C06866; D00250; AB00053098-11; AB00053098_12; Capsaicin, from Capsicum sp., >=50% (HPLC); EN300-7544118; 826 - Capsaicin and heat units in chilli powder; CAPSAICIN (CONSTITUENT OF CAPSICUM) [DSC]; Q273169; SR-05000001861-1; SR-05000001861-4; SR-05000001861-5; SR-05000001861-6; SR-05000001861-9; BRD-K37056290-001-01-1; BRD-K50590187-001-06-6; Capsaicin, certified reference material, TraceCERT(R); Flavor and Extract Manufacturers' Association No. 3404; Capsaicin, European Pharmacopoeia (EP) Reference Standard; N-(4-hydroxy-3-methoxyphenylmethyl)-8-Methyl-6-Nonenamide; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Capsaicin, United States Pharmacopeia (USP) Reference Standard; Capsaicin; 8-Methyl-N-vanillyl-trans-6-nonenamide; NGX-4010; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-(E)-; N-(4-HYDROXY-3-METHOXYBENZYL)-8-METHYL-6-NONENAMIDE [FHFI]; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; 6-nonenamide,n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-,(6e)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material
Click to Show/Hide
|
||||
Structure |
![]() |
||||
Formula |
C18H27NO3
|
||||
IUPAC Name |
(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
|
||||
Canonical SMILES |
CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
|
||||
InChI |
InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
|
||||
InChIKey |
YKPUWZUDDOIDPM-SOFGYWHQSA-N
|
||||
PubChem CID |
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 | |
Response regulation | Capsaicin inhibited the proliferation of A549 and NCI-H23 cells and induced ferroptosis by inactivating SLC7A11/GPX4 signaling. Capsaicin could be used as a potential anticancer agent in the treatment of non-small cell lung cancer (NSCLC). | |||
Cystine/glutamate transporter (SLC7A11)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 | |
Response regulation | Capsaicin inhibited the proliferation of A549 and NCI-H23 cells and induced ferroptosis by inactivating SLC7A11/GPX4 signaling. Capsaicin could be used as a potential anticancer agent in the treatment of non-small cell lung cancer. | |||